GlassScriptPhysician profile
Thao Tam Dang
NPI 1285282079
$4,422.45
in general payments reported to CMS, 2019-2025
36 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,387 · 2024: $1,569 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,266 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,266.32 |
| Education | $156.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $919.17 | 2023-2025 | |
| Novo Nordisk INC | $563.10 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $364.46 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $260.33 | 2023-2024 | Nucala, Shingrix, Arexvy |
| Amgen INC. | $251.43 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $248.93 | 2023-2025 | Breztri, Airsupra |
| Renalytix Ai, INC. | $176.05 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $127.31 | 2025 | Veozah |
| Pfizer INC. | $124.99 | 2023-2025 | |
| Gilead Sciences, INC. | $121.83 | 2023 | |
| Merck Sharp & Dohme LLC | $115.04 | 2023-2025 | Verquvo, Gardasil 9, Belsomra |
| Corium, LLC | $107.90 | 2023-2025 | Azstarys |
| Ibsa Pharma INC. | $100.95 | 2023-2025 | Tirosint, Licart, Tirosint |
| Exact Sciences Corporation | $87.03 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $82.14 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $75.80 | 2023-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $70.44 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $65.64 | 2024-2025 | Nuzyra |
| Azurity Pharmaceuticals, INC. | $65.07 | 2023 | Adthyza, Edarbi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.37 | 2025 | Caplyta |
| Stryker Corporation | $50.09 | 2025 | Clottriever Bold Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.50 | 2023-2024 | Jardiance |
| Coloplast Corp | $45.66 | 2023 | Titan, Altis |
| Medtronic, INC. | $41.75 | 2023-2024 | Intellis Adaptivestim |
| Avvisto Therapeutics, LLC | $34.46 | 2025 | Cycloset |
| Antares Pharma, INC. | $31.76 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Averitas Pharma INC. | $29.15 | 2025 | Qutenza |
| Seqirus USA INC | $26.77 | 2024 | Flucelvax, Fluad |
| Esperion Therapeutics, INC. | $20.36 | 2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.31 | 2024 | Xifaxan |
| Inspire Medical Systems, INC. | $18.60 | 2024 | Inspire |
| Alkermes, INC. | $18.09 | 2025 | Lybalvi |
| Ironshore Pharmaceuticals INC. | $15.37 | 2023 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2023 | Seglentis |
| Currax Pharmaceuticals LLC | $14.68 | 2025 | Contrave |
| Vanda Pharmaceuticals INC. | $13.12 | 2023 | Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thao Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.